The Robert Ramsay laboratory specialises in transcriptional control, stem cell biology and models of colorectal cancer (CRC), peroneal cancers (for example, anal and penile SCCs) and their metastasis. We were the first in Australia (and amongst the first internationally) to publish on the application of mouse and human organoid cultivation, drug testing and stem cell properties. This includes the development of tumoroids from rectal cancers, liver and peritoneal mets combined with immune cells.
A particular and long-standing research interest has been on the MYB transcription factor family. We have led the field in the role of these factors in stem cell function and the regulation of differentiation particularly outside the blood system. To this end we are the first to conduct and complete a clinical trial directly targeting MYB in CRC and adenoid cystic carcinoma. The lab works very closely with Peter Mac-based and other clinicians co-supervising clinician PhD students and scientists.
Over the fifteen years the lab has also focused on clinical trials employing immunotherapy combined with radiotherapy. Additionally, the team has advanced laparoscopic cancer surgery optimisation as it relates to metastasis. The lab has been deeply engaged in eight completed trials, two are ongoing and two imminent.
Current project
We are currently completing a range of investigational studies coupled to clinical trials, advancing the use of new therapies for peroneal SCCs and initiating proof of principle studies employing tumoroid drug testing platforms embedded in clinical settings.